Good morning, ladies and gentlemen. Welcome to this annual and special meeting of the shareholders of Fennec Pharmaceuticals Inc. I'm Khalid Islam, the Chairman of the Board of the company, and I'll be chairing this meeting. I'd like to call the meeting to order. We'll begin with the formal legal business of the meeting. After the formal business has been concluded, our CEO, Mr. Jeff Hackman, will provide an update on the company's business progress, following which we'll hold a Q&A session where you'll have an opportunity to ask questions from management. As chairman, I appoint Bradley Taylor to act as Secretary and Scrutineer for this meeting. The notice calling this meeting, together with the related management proxy circular, dated April 28th, 2026, and form of proxy were delivered to shareholders as required by statute. I've received a statutory declaration from Broadridge attesting to the mailing, and I direct the secretary to attach the declaration to the minutes of this meeting. The notice and the circular are available online. Accordingly, I'll dispense with the reading of the notice. I've been advised by the scrutineer that a quorum is present, and the scrutineer's preliminary report on the attendance at this meeting has now been received. I therefore declare this meeting to be properly constituted for the transaction of business. I direct that the scrutineer's report on attendance be attached to the minutes of the meeting. I would like to remind everyone that only registered shareholders or proxy holders can move or second motions, ask questions, make comments, or vote. In proceeding with the business of the meeting, we will, in accordance with the British Columbia Business Corporations Act, proceed to conduct votes by poll. Please click the Vote Here button on your screen when the poll is announced. This will allow you to choose to vote on each resolution immediately or wait until conclusion of discussion on each resolution prior to casting your votes. To submit a question, type your question in the Ask a Question text box. Once discussion on all items of business has concluded, I'll give you some time to enter your votes, and then I'll declare the voting closed on all resolutions. Please note that if you voted your shares by proxy prior to the start of the meeting, your vote has been received by the scrutineer, and there is no need to vote those shares again during the meeting, unless you wish to revoke or change your vote. The first item of business is the presentation of the financial statements of the company for the year ending December 31, 2025, and the auditor's report thereon. A copy of the company's 2025 annual report, which includes the annual financial statements, management's discussion and analysis of operating results, and the auditor's report, has been mailed to shareholders, and I don't propose to read it. The next item of business is the election of directors. Five directors are to be elected, and information regarding the nominees proposed for management is set out in the management proxy circular, which accompanied the notice of meeting sent to shareholders. The nominees are Khalid Islam, Chris Rallis, Marco Brughera, Jodi Cook, and Jeff Hackman. Are there any further nominations? As there are no further nominations, will someone move that the nominations be closed? Mr. Chairman, I so move. Thank you. Would someone second the motion? Mr. Chairman, I second the motion. I declare the nominations closed and request a motion to elect the nominees set out in the circular as directors of Fennec. Mr. Chairman, I so move. Thank you. Would someone second the motion? Mr. Chairman, I second the motion. A motion has been made and seconded to elect those nominated directors. Is there any discussion? If you haven't already, shareholders may now vote on the motion by clicking the voting button on your screen. You may instead wait until all motions have been presented. In either case, the votes will be tabulated, and at the end of the meeting, I'll report the result. We'll now proceed with the appointment of auditors. May I have a motion that Haskell & White be appointed as auditors of the company and that the directors be authorized to fix their remuneration? Mr. Chairman, I so move. Thank you. Would someone second the motion? I second the motion. Thank you. Is there any discussion? Thank you. If you haven't already, shareholders may now vote on the motion by clicking the voting button on your screen or wait until all motions have been presented. Our next item of business is the approval of the compensation of the company's named executive officers as disclosed in the management information circular, which accompanied the notice of meeting sent to shareholders. This vote is advisory and therefore not binding on the company, the board, or the compensation committee. Shareholders are being asked to consider an ordinary resolution that the compensation paid to the company's named executive officers, as disclosed in the circular pursuant to Item 402 of Regulation S-K, including the executive compensation, the compensation tables, and narrative be approved. I'll now ask for a motion to approve this ordinary resolution. Mr. Chairman, I so move. Thank you. Would someone second the motion? I second the motion. Thank you. Is there any discussion? Thank you. If you haven't already, shareholders may now vote on the motion or wait until all motions have been presented. Our next item of business is the approval of the frequency of advisory votes on compensation of the company's named executive officers, as discussed in the management information circular, which accompanied the notice of the meeting sent to the shareholders. This vote is advisory and therefore not binding on the company, the board, or the compensation committee. Shareholders are being asked to consider an ordinary resolution that an advisory vote on executive compensation be held every one year, as discussed in the circular, be approved. I'll now ask for a motion to approve this ordinary resolution. Mr. Chairman, I so move. Thank you. Would someone second the motion? I second the motion. Thank you. Is there any discussion? Thank you. If you haven't already, shareholders may now vote on the motion or wait until all motions have been presented. Our next item of business is the approval of certain amendments to the Fennec 2020 Equity Incentive Plan. In particular, shareholders are being asked to consider an ordinary resolution, excluding certain insiders whose votes will not be counted, the proposed increase to the option pool under Fennec's 2020 Equity Incentive Plan, the details of which are described in the management information circular, which accompanied the notice of the meeting sent to the shareholders. I'll now ask for a motion to approve this ordinary resolution. Mr. Chairman, I so move. Thank you. Would someone second the motion? I second the motion. Thank you. Is there any discussion? Thank you. If you haven't already, shareholders may now vote on the motion or wait until all motions have been presented. Our next item of business is to ratify and approve the adoption of Fennec's 2026 Equity Inducement Plan. In particular, shareholders are being asked to consider an ordinary resolution to approve the 2026 Equity Inducement Plan, the details of which are described in the management information circular, which accompanied the notice of meeting sent to shareholders. I'll now ask for a motion to approve this ordinary resolution. Mr. Chairman, I so move. Thank you. Would someone second the motion? I second the motion. Thank you. Is there any discussion? If there is no further discussion, we'll move to a vote on all matters presented to the meeting. Please click the voting button on your screen in order to vote on each resolution, if you haven't already. 20 seconds have passed. We'll be wrapping up voting in another 10 seconds. Now that everyone has had the opportunity to vote, I now declare the polls closed. We'll now take a moment to determine the results of the polls. Mr. Chairman, this is the scrutineer. I can confirm that all motions have passed. Thank you. In light of the voting results, I declare the motion to elect directors, the motion to appoint auditors, the advisory vote on executive compensation, the advisory vote on the frequency of advisory votes on executive compensation, the amendment to the Equity Incentive Plan, the ratification of the Equity Inducement Plan, are all carried. All of the business for which this annual and special meeting was called has been completed. Is there any other business? That concludes the formal business scheduled to come before the meeting. I remind you that there will be a management presentation following this formal portion and an opportunity to ask questions after that. I'll now declare the annual and special meeting adjourned, and I'll hand over to Mr. Jeff Hackman, our CEO, to go through the management presentation. Thank you all so very much. Thank you. Good morning, everyone. Before we begin the informal part of our meeting today, I would like to remind you that our remarks and answers to your questions may contain forward-looking information about the future events or the company's future performance. The information, by its nature, is subject to risks and uncertainties. Further information on these risks and uncertainties is available in the company's relevant filings, which are available on EDGAR and SEDAR. Good morning. I'm Jeff Hackman, Chief Executive Officer and Director of Fennec Pharmaceuticals. Thank you for being a Fennec shareholder and joining our annual meeting. 2025 was truly a defining year for Fennec. Our results validate that our strategy is clear, and the foundation we've built since I joined the company in late 2024 is now propelling Fennec into its next chapter of growth. To briefly summarize our 2025 performance, we delivered record net product sales, achieved significant growth within Fennec HEARS, which is our full-service patient support program, and advanced our independent clinical evidence generation for PEDMARK, all while driving quarter-over-quarter growth. Importantly, we also strengthened our financial position in 2025. Through prudent operating decisions and strategic financial initiatives, including the completion of an oversubscribed $42 million equity offerings with participation from new and existing investors, along with full debt redemption. One of the most exciting developments for Fennec continues to be the interest and adoption of PEDMARK in the adolescent and young adult, or AYA segment, which presents a significant opportunity. As a reminder, PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized and non-metastatic tumors. PEDMARK is recommended for the AYA population by the National Comprehensive Cancer Network, or NCCN, with a 2A endorsement. As we previously shared, the market potential for AYA is greater than the size of the pediatric market and has a favorable reimbursement profile via outpatient reimbursement. We've made several important strategic enhancements to the business that are clearly strengthening our execution across the entire organization and expanding our reach. In late Q4 2025, we launched an initiative called Project Ignite to expand our customer-facing team to reach with greater frequency and larger prescriber target base, increasing from 1,300 to now over 5,000 targets. More specifically, much of the first quarter 2026 involved the foundation work required to bring those investments fully online, recruiting, onboarding new talent, completing training, integrating these teams and these members into our commercial model. The recruitment and onboarding process concluded at our national meeting in early March. This was an important milestone to align the expanded organization around the strategy, sharpen our execution, and ensure the team entered the field equipped and ready to execute. There is a natural ramp period with any field force expansion, and we view much of Q1 as laying that groundwork. We know the AYA market is promotionally sensitive, and effectively communicating the unmet need around cisplatin-induced ototoxicity, or CIO, is our number one priority. This creates a pathway for practices to help change the standard of care for all appropriate patients receiving cisplatin. We have strong momentum in early 2026, as evidenced by our recently reported Q1 results, including net product sales of $15.1 million for the first quarter of 2026, compared to $8.8 million in the first quarter of 2025, representing an increase of approximately 73% year-over-year. We saw record patient enrollments in Q1, and in April 2026, this was our highest demand month ever. We are encouraged by the trajectory we are on, having delivered six consecutive quarters of strong performance to date. We are executing in Q2 of this year with a strengthened commercial footprint that is now positioned to drive greater impact through increased reach, frequency, and account penetration. PEDMARK continues to gain traction in major academic centers and large community practices, which are integrating PEDMARK into the treatment plans, further validating clinical utility and expanding patient access in real-world settings. Beyond commercial execution, we are encouraged by the growing clinical interest in independently evaluating PEDMARK across new patient populations and tumor types, which reinforces our confidence in broader potential. Within the last few months, we've announced the initiation of three studies with leading and highly respected academic centers and community oncology centers in the U.S. We believe the data and insights generated through these studies, and others to come, will help support broader clinical adoption of PEDMARK to prevent ototoxicity or permanent hearing loss in AYA and adult cancer patients receiving cisplatin-based treatments. Additionally, four abstracts from key opinion leaders evaluating the utility of PEDMARK in preventing CIO were just presented at the 2026 American Society of Clinical Oncology, or ASCO's, annual meeting. These studies represent an important step forward in addressing the critical and unmet need, and highlight Fennec's ongoing commitment to expanding the evidence-based supporting use and integration of PEDMARK into preventing CIO in additional patient populations and tumor types. On the global front, in addition to our Norgine partnership in Europe and Australia and New Zealand, we are encouraged by the results announced in December in 2025 from the investigator-initiated clinical trial in Japan, STS-J01, evaluating PEDMARK. We are encouraged in these discussions to evaluate potential strategic options for bringing this product to patients in Japan as soon as possible. We are focused on identifying a right path forward that maximizes the long-term value of this asset. Importantly, in March 2026, Fennec announced that it entered into agreement with Cipla Limited, or Cipla USA Inc., to settle the litigation between them regarding Cipla's application to the FDA for approval to make a generic version of Fennec's PEDMARK product no earlier than September 2023. Fennec is pleased to announce we have resolution of this matter. As a reminder, Fennec has patents globally providing protection until 2039. In closing, we believe our performance and progress reflect meaningful momentum across the business and reinforces our confidence in 2026 as an important year for Fennec. With strong execution underway in Q2, we have multiple catalysts ahead. We remain focused on delivering sustained value. Thank you for your continued support in Fennec Pharmaceuticals.